Jaime Hernandez-Montfort, MD
Cardiovascular Disease · Round Rock, TXNPI 1235389149
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Abiomed accounts for 77.9% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $44,078 and has fallen 92.0% since, to $3,513 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 229 payments — averaging $537.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$96K
- Abbott$18K
- Boston Scientific$6K
- Biotronik Inc.$640
- Edwards Lifesciences$292
- Medtronic$283
- plus $1K from 13 others
Across 23 payments — averaging $4355.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nuwellis, Inc.$57K
- Abbott$38K
- Novartis$6K
What the payments were for
- Consulting fees$16,00013%
- Speaking & faculty fees$71,45058%
- Travel & lodging$26,43021%
- Food & beverage$9,2368%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 122 | $95,860 |
| Abbott | 57 | $18,175 |
| Boston Scientific | 7 | $6,488 |
| Biotronik Inc. | 6 | $640 |
| Edwards Lifesciences | 3 | $292 |
| Medtronic(2 entities) | 4 | $283 |
| Novartis | 11 | $195 |
| Impulse Dynamics (USA) Inc. | 2 | $195 |
| Akcea Therapeutics, Inc. | 2 | $186 |
| Nuwellis, Inc. | 1 | $185 |
| Amgen | 2 | $142 |
| Scpharmaceuticals Inc. | 1 | $125 |
| Endotronix, Inc. | 1 | $111 |
| Cvrx, Inc. | 2 | $96 |
| AstraZeneca | 2 | $43 |
| Johnson & Johnson | 2 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Bayer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$93,344
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$15,940
- CARDIOMEMS$899
- BioMonitor$373
- OPTIMIZER$341
- HeartMate$265
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$262
- Rivacor 7 DR-T$248
- Solia$248
- Rivacor$248
- Edora$248
- Acticor$248
- AQUADEX SMARTFLOW CONSOLE$185
- HeartMate 3 Left Ventricular Dev$138
- CoreValve Evolut$127
- Acticor 7 VR-T DX$126
- Zero Gravity$126
- FUROSCIX$125
- Repatha$122
- TEGSEDI$116
How this compares
$123,116 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 266 | $255,611 |
| JardianceEmpagliflozin | 148 | $156,096 |
| EliquisApixaban | 49 | $38,203 |
| FarxigaDapagliflozin Propanediol | 29 | $25,871 |
| Envarsus XrTacrolimus | 15 | $19,206 |
| OzempicSemaglutide | 15 | $14,340 |
| XareltoRivaroxaban | 11 | $7,011 |
| Tacrolimus | 13 | $6,442 |
| Torsemide | 203 | $4,189 |
| Metoprolol Succinate | 154 | $2,921 |
| Amiodarone Hcl | 38 | $2,187 |
| Valsartan | 50 | $1,876 |
| Spironolactone | 247 | $1,824 |
| Eplerenone | 18 | $1,360 |
| Atorvastatin Calcium | 74 | $1,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $195 | $255,611266 claims |
| AstraZenecaFarxiga | $43 | $25,87129 claims |
| Johnson & JohnsonXarelto | $37 | $7,01111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Round Rock
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.